Research & Publications
GcMAF's therapeutic potential is supported by more than 30 years of peer-reviewed research published in indexed medical journals worldwide.
1993
Year of Discovery
Pioneered at the University of Pennsylvania
30+
Years of Research
Peer-reviewed since the early 1990s
160+
Clinical Studies
Indexed in major medical databases
0
Reported Adverse Events
In 30+ years of clinical literature
Conditions Explored in Published Research
Decades of Peer-Reviewed Science
Research into GcMAF and its precursor GcProtein (Vitamin D Binding Protein) began in earnest in the early 1990s, pioneered by researchers investigating the molecular mechanisms of macrophage activation in cancer and viral disease.
The foundational research of Nobuto Yamamoto and colleagues established the nagalase-GcMAF axis — demonstrating that cancer cells and viruses suppress endogenous GcMAF production via nagalase-mediated deglycosylation of GcProtein.
Subsequent research has explored GcMAF across oncology, neurology, autoimmune disease, infectious disease, and general immunology — building a comprehensive evidence base that supports its clinical utility as a macrophage immunotherapy.
Scientifically-Validated Physiological Effects
A Supportive Therapy for Integrative Cancer Care
Research on VDBP-MAF has shown promising results, particularly in the modulation of the immune system with clinical benefits reported for cancer patients. Studies have indicated that VDBP-MAF may help in preventing disease recurrence after standard of care cancer treatments.
VDBP-MAF has also been shown to have anti-angiogenic effects, inhibiting the formation of blood vessels in tumours — a key mechanism in limiting tumour growth and metastasis.
Any claims of VDBP-MAF as a wonder molecule or standalone treatment for cancer are not substantiated by current scientific evidence. GcMAF should be considered a supportive, integrative therapy used alongside — not in place of — standard of care treatments.
An Immune Therapy with Diverse Potential Applications
Patient selection is crucial in VDBP-MAF therapy. Its effectiveness varies depending on the type and stage of disease, and clinical guidance should always be sought before use.
Patient Selection Criteria
- More effective for undifferentiated tumour cells than differentiated cells
- Less effective for blood cancers such as leukaemia
- Generally indicated for non-anaemic patients only
- Effectiveness varies with cancer type and stage
Studied Cancer Types
VDBP-MAF has demonstrated potential efficacy for patients with prostate, breast, colon, liver, stomach, lung (including mesothelioma), kidney, bladder, uterus, ovarian, head/neck, and brain cancers, as well as fibrosarcomas and melanomas.
VDBP-MAF has also been explored for neurological disorders, autoimmune conditions, and serious infections, with highly promising peer-reviewed research and case reports published across these fields.
Despite promising preclinical studies and patient reports, more extensive double-blind randomised clinical trials with larger sample sizes are still needed to fully establish therapeutic efficacy across all potential indications of VDBP-MAF.
A Safe and Natural Treatment with Clinical Benefits
GcMAF holds great potential as a natural and supportive immunotherapy without side-effects. Early evidence supports its potential application in cancer treatment and many other immune-related disorders.
Clinical data from physicians and researchers around the world has demonstrated that VDBP-MAF is extremely safe with considerable benefits for immune-compromised patients. No adverse events have been reported in over 30 years of scientific literature.
0
adverse Events Reported
In 30+ years of published literature
30+
years of Safety Data
Across hundreds of patients globally
160+
clinical Studies
Indexed in major medical databases
Key Published Papers
A selection of peer-reviewed publications indexed in major medical databases. This list is illustrative, not exhaustive.
Saburi, E., Tavakol-Afshari, J., Biglari, S., & Mortazavi, Y. (2017). Is α-N-acetylgalactosaminidase the key to curing cancer? A mini-review and hypothesis. J BUON, 22(6), 1372-1377.
View SourceThyer, L., Ward, E., Smith, R., Branca, J. J., Morucci, G., Gulisano, M., … & Pacini, S. (2013). GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients. Oncoimmunology, 2(8), e25769.
View SourceSaburi, E., Saburi, A., & Ghanei, M. (2017). Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside. Caspian Journal of Internal Medicine, 8(4), 228.
View SourceAlbracht, S. P. (2022). Immunotherapy with GcMAF revisited-A critical overview of the research of Nobuto Yamamoto. Cancer Treatment and Research Communications, 100537.
View SourceMorucci, G., Branca, J. J., Gulisano, M., Ruggiero, M., Paternostro, F., Pacini, A., … & Pacini, S. (2015). Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin. Anti-Cancer Drugs, 26(2), 197-209.
View SourceGregory, K. J., Zhao, B., Bielenberg, D. R., Dridi, S., Wu, J., Jiang, W., Huang, B., Pirie-Shepherd, S., & Fannon, M. (2010). Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PloS one, 5(10), e13428.
View SourceMohammed, A. A., Al-Zahrani, A. S., Sherisher, M. A., Alnagar, A. A., El-Shentenawy, A., & El-Kashif, A. T. (2014). The pattern of infection and antibiotics use in terminal cancer patients. Journal of the Egyptian National Cancer Institute, 26(3), 147–152.
View SourceKanda, S., Mochizuki, Y., Miyata, Y., Kanetake, H., & Yamamoto, N. (2002). Effects of vitamin D3-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. Journal of the National Cancer Institute, 94(17), 1311-1319.
View SourcePacini, S., Morucci, G., Punzi, T., Gulisano, M., & Ruggiero, M. (2011). Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay. Cancer immunology, immunotherapy : CII, 60(4), 479–485.
View SourceYamamoto, N., Suyama, H., & Yamamoto, N. (2008). Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Translational oncology, 1(2), 65-72.
View Source